HitGen Overview
- Year Founded
-
2012
- Status
-
Public
- Employees
-
546
- Stock Symbol
-
688222
- Investments
-
5
- Share Price
-
$3.88
- (As of Friday Closing)
HitGen General Information
Description
HitGen Inc is dedicated to building a world-class biopharmaceutical enterprise. Its mission is to advance human health and quality of life. It provides therapeutic solutions to address unmet medical needs. Centered on its internationally DEL (DNA-encoded Library) technology, the Company has expanded into Fragment-Based Drug Discovery and Structure-Based Drug Design and a suite of complementary platforms based on Oligonucleotide-based Therapeutics, Targeted Proximity Drugs, and Cyclic Peptidomimetics. The group has developed HAILO, a proprietary "DEL+AI+Automation" molecular optimization platform, thereby establishing a distinctive novel molecule discovery engine that delivers both therapeutic molecules and tool molecules to the world-wide pharmaceutical industry.
Contact Information
Website
www.hitgen.comCorporate Office
- Building C2, NO.8, Huigu 1st East Road
- Tianfu International Bio-Town, Shuangliu District
- Chengdu, Sichuan 610200
- China
Corporate Office
- Building C2, NO.8, Huigu 1st East Road
- Tianfu International Bio-Town, Shuangliu District
- Chengdu, Sichuan 610200
- China
HitGen Stock Performance
As of 20-Nov-2026, HitGen’s stock price is $3.88. Its current market cap is $1.56B with 401M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.88 | $3.99 | $3.02 - $7.10 | $1.56B | 401M | 23.1M | $0.06 |
HitGen Financials Summary
As of 30-Sep-2026, HitGen has a trailing 12-month revenue of $102M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 2,575,913 | 1,235,614 | 581,310 | 753,791 |
| Revenue | 102,392 | 73,084 | 59,507 | 52,485 |
| EBITDA | 22,950 | 22,251 | 14,492 | 11,839 |
| Net Income | 22,640 | 15,227 | 7,157 | 5,755 |
| Total Assets | 333,994 | 279,374 | 240,615 | 243,992 |
| Total Debt | 63,954 | 33,481 | 29,309 | 32,869 |
HitGen Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
HitGen Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
HitGen Comparisons
Industry
Financing
Details
HitGen Competitors (44)
One of HitGen’s 44 competitors is Eikon Therapeutics, a Formerly VC-backed company based in Millbrae, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Eikon Therapeutics | Formerly VC-backed | Millbrae, CA | ||||
| Eurofins DiscoverX Products | Formerly VC-backed | Fremont, CA | ||||
| Genesis Molecular AI | Venture Capital-Backed | San Mateo, CA | ||||
| Miltenyi Biotec | Private Debt Financed | Bergisch Gladbach, Germany | ||||
| Horizon Discovery | Formerly VC-backed | Cambridge, United Kingdom |
HitGen Patents
HitGen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026145630-A1 | Spiro compound and use thereof | Pending | 31-Dec-2024 | ||
| WO-2026145632-A1 | Spirocyclic compound and use thereof | Pending | 31-Dec-2024 | ||
| US-20260176303-A1 | Blocking peptides and related methods, formulations, and compositions | Pending | 25-Dec-2024 | ||
| EP-4821919-A1 | Modified nucleotide monomer and use thereof | Pending | 08-Jan-2024 | ||
| WO-2025148770-A1 | Modified nucleotide monomer and use thereof | Inactive | 08-Jan-2024 | C07D233/90 |
HitGen Signals
HitGen Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
HitGen Investments & Acquisitions (5)
HitGen’s most recent deal was a Early Stage VC with Connexus Therapeutics. The deal was made on 17-Sep-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Connexus Therapeutics | 17-Sep-2026 | Early Stage VC | Drug Discovery | ||
| Leaderna Therapeutics | 13-Mar-2026 | Early Stage VC | Drug Discovery | ||
| CrystalO Biopharma | 07-Jan-2022 | Early Stage VC | Drug Discovery | ||
| Vernalis | 02-Dec-2020 | Merger/Acquisition | Biotechnology | ||
| NetVation | 31-Dec-2018 | Merger/Acquisition | Drug Discovery |
HitGen ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
HitGen Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| NetVation | Chengdu, China | 2017 | |
| Vernalis | Cambridge, United Kingdom | 1986 |
HitGen FAQs
-
When was HitGen founded?
HitGen was founded in 2012.
-
Where is HitGen headquartered?
HitGen is headquartered in Chengdu, China.
-
What is the size of HitGen?
HitGen has 546 total employees.
-
What industry is HitGen in?
HitGen’s primary industry is Discovery Tools (Healthcare).
-
Is HitGen a private or public company?
HitGen is a Public company.
-
What is HitGen’s stock symbol?
The ticker symbol for HitGen is 688222.
-
What is the current stock price of HitGen?
As of 20-Nov-2026 the stock price of HitGen is $3.88.
-
What is the current market cap of HitGen?
The current market capitalization of HitGen is $1.56B.
-
What is HitGen’s current revenue?
The trailing twelve month revenue for HitGen is $102M.
-
Who are HitGen’s competitors?
Eikon Therapeutics, Eurofins DiscoverX Products, Genesis Molecular AI, Miltenyi Biotec, and Horizon Discovery are some of the 44 competitors of HitGen.
-
What is HitGen’s annual earnings per share (EPS)?
HitGen’s EPS for 12 months was $0.06.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process